NCT07053202Completed
TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma
Clinical Study on TACE Combined With Immune Agents for Inhibiting Tumor Angiogenesis in Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 8 Jul 2025
Brief summary (registry, in English)
This study investigates the clinical efficacy and safety of transarterial chemoembolization (TACE) combined with the immune agent nivolumab compared to TACE alone for treating hepatocellular carcinoma (HCC). The study aims to determine if the combination therapy can more effectively inhibit tumor angiogenesis, improve clinical benefit rates, and prolong survival, while maintaining a high safety profile.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 140 (actual)
- First submitted
- 19 Jun 2025
- Start date
- 1 Oct 2021
- Primary completion date
- 1 Nov 2022
- Lead sponsor
- The First Hospital of Hebei Medical University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07053202
What you commit to
- Study type: Interventional
- Participants enrolled: 140
- From 1 Oct 2021 to the primary completion date, 1 Nov 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous treatment with other antitumor therapies, including surgery, radiotherapy, chemotherapy, targeted therapy, or immunotherapy;
- Enrollment in another clinical trial or participation in a clinical trial within one month prior to admission;
Other illness
- Recurrent liver cancer or metastatic cancer from other organs;
- History of other malignant tumors;
- Human immunodeficiency virus (HIV) infection;
- Severe cardiovascular, pulmonary, cerebral, or renal diseases;
- Active bleeding or coagulopathy outside the liver;
- Psychiatric disorders or unstable mental status;
- Allergic reactions to the study drugs;
- Severe gastrointestinal diseases, such as active ulcers, or other conditions affecting drug absorption.
Other
- Pregnant or lactating women;
Who the study is looking for
- Age \>18 years;
- Diagnosis of HCC according to the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition), confirmed by pathological examination;
- Barcelona Clinic Liver Cancer (BCLC) stages A, B, and C, with non-resectable tumors;
- Liver function graded as Child-Pugh A or B;
- At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1;
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2;
- No severe hematologic abnormalities or immune deficiencies;
- Expected survival time \>6 months.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Hospital of Hebei Medical University Coordinator of this site? Confirm its status | Shijiazhuang | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.